Is IO Biotech, Inc. (IOBT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 8.9% / 30% | 277.7% / 30% | 5.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 8.9% / 33% | 277.7% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.8% / 33% | 88.7% / 33% | 1.7% / 33% | N/A | ✗ NOT HALAL |
| S&P | 8.9% / 33% | 277.7% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.8% / 33% | 88.7% / 33% | 1.7% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -240.5% | |
| Return on Assets (ROA) | -88.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$82M |
| Free Cash Flow | -$82M |
| Total Debt | $2M |
| Debt-to-Equity | 1988.9 |
| Current Ratio | 2.0 |
| Total Assets | $68M |
Price & Trading
| Last Close | $0.20 |
| 50-Day MA | $0.31 |
| 200-Day MA | $0.98 |
| Avg Volume | 10.4M |
| Beta | 0.4 |
|
52-Week Range
$0.14
| |
About IO Biotech, Inc. (IOBT)
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is IO Biotech, Inc. (IOBT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), IO Biotech, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is IO Biotech, Inc.'s debt ratio?
IO Biotech, Inc.'s debt ratio is 8.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.8%.
What are IO Biotech, Inc.'s key financial metrics?
IO Biotech, Inc. has a market capitalization of $14M. Return on equity stands at -240.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.